GALAPAGOS NV (GLPG.AS) Stock Fundamental Analysis
Europe - Euronext Amsterdam - AMS:GLPG - BE0003818359 - Common Stock
26.54 EUR
+0.02 (+0.08%)
Overall GLPG gets a fundamental rating of 2 out of 10. We evaluated GLPG against 77 industry peers in the Biotechnology industry. The financial health of GLPG is average, but there are quite some concerns on its profitability. GLPG has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year GLPG has reported negative net income.
In the past year GLPG has reported a negative cash flow from operations.
In multiple years GLPG reported negative net income over the last 5 years.
GLPG had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
GLPG has a Return On Assets of -12.41%. This is in the better half of the industry: GLPG outperforms 65.38% of its industry peers.
GLPG has a better Return On Equity (-17.82%) than 70.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.41% | ||
| ROE | -17.82% | ||
| ROIC | N/A |
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GLPG's Profit Margin has improved in the last couple of years.
The Gross Margin of GLPG (84.25%) is better than 73.08% of its industry peers.
GLPG's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for GLPG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.68%
GM growth 3Y-4.31%
GM growth 5YN/A
2. Health
2.1 Basic Checks
GLPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GLPG remains at a similar level compared to 1 year ago.
Compared to 5 years ago, GLPG has more shares outstanding
Compared to 1 year ago, GLPG has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.49, we must say that GLPG is in the distress zone and has some risk of bankruptcy.
GLPG's Altman-Z score of 1.49 is fine compared to the rest of the industry. GLPG outperforms 67.95% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that GLPG is not too dependend on debt financing.
GLPG has a better Debt to Equity ratio (0.00) than 89.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.49 |
ROIC/WACCN/A
WACC7.88%
2.3 Liquidity
GLPG has a Current Ratio of 8.62. This indicates that GLPG is financially healthy and has no problem in meeting its short term obligations.
GLPG has a Current ratio of 8.62. This is amongst the best in the industry. GLPG outperforms 89.74% of its industry peers.
GLPG has a Quick Ratio of 8.55. This indicates that GLPG is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of GLPG (8.55) is better than 89.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.62 | ||
| Quick Ratio | 8.55 |
3. Growth
3.1 Past
GLPG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -311.50%.
Measured over the past years, GLPG shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -12.47% on average per year.
Looking at the last year, GLPG shows a very negative growth in Revenue. The Revenue has decreased by -43.08% in the last year.
Measured over the past years, GLPG shows a very negative growth in Revenue. The Revenue has been decreasing by -20.82% on average per year.
EPS 1Y (TTM)-311.5%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-298.7%
Revenue 1Y (TTM)-43.08%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%18.9%
3.2 Future
The Earnings Per Share is expected to decrease by -40.64% on average over the next years. This is quite bad
The Revenue is expected to decrease by -7.07% on average over the next years.
EPS Next Y-346.2%
EPS Next 2Y-95.96%
EPS Next 3Y-65.78%
EPS Next 5Y-40.64%
Revenue Next Year-5.39%
Revenue Next 2Y-2.52%
Revenue Next 3Y-3.52%
Revenue Next 5Y-7.07%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
GLPG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLPG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as GLPG's earnings are expected to decrease with -65.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-95.96%
EPS Next 3Y-65.78%
5. Dividend
5.1 Amount
No dividends for GLPG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AMS:GLPG (11/21/2025, 7:00:00 PM)
26.54
+0.02 (+0.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners25.23%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap1.75B
Revenue(TTM)286.76M
Net Income(TTM)-436.00M
Analysts48.24
Price Target29.75 (12.09%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10823.9%
Min EPS beat(2)-19965.4%
Max EPS beat(2)-1682.53%
EPS beat(4)1
Avg EPS beat(4)-5642.06%
Min EPS beat(4)-19965.4%
Max EPS beat(4)154.1%
EPS beat(8)4
Avg EPS beat(8)-2655.53%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.56%
Min Revenue beat(2)-10.27%
Max Revenue beat(2)-2.86%
Revenue beat(4)1
Avg Revenue beat(4)-5.15%
Min Revenue beat(4)-11.82%
Max Revenue beat(4)4.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.83%
PT rev (3m)0.83%
EPS NQ rev (1m)55.69%
EPS NQ rev (3m)55.69%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0.15%
Revenue NQ rev (3m)0.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.1 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.71 | ||
| P/tB | 0.72 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.62
EYN/A
EPS(NY)-2.06
Fwd EYN/A
FCF(TTM)-4.36
FCFYN/A
OCF(TTM)-4.08
OCFYN/A
SpS4.35
BVpS37.13
TBVpS37.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.41% | ||
| ROE | -17.82% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.25% | ||
| FCFM | N/A |
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.68%
GM growth 3Y-4.31%
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 40% | ||
| Cap/Sales | 6.28% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.62 | ||
| Quick Ratio | 8.55 | ||
| Altman-Z | 1.49 |
F-Score2
WACC7.88%
ROIC/WACCN/A
Cap/Depr(3y)93.92%
Cap/Depr(5y)187.53%
Cap/Sales(3y)17%
Cap/Sales(5y)15.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-311.5%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-298.7%
EPS Next Y-346.2%
EPS Next 2Y-95.96%
EPS Next 3Y-65.78%
EPS Next 5Y-40.64%
Revenue 1Y (TTM)-43.08%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%18.9%
Revenue Next Year-5.39%
Revenue Next 2Y-2.52%
Revenue Next 3Y-3.52%
Revenue Next 5Y-7.07%
EBIT growth 1Y-67.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.52%
EBIT Next 3Y-12.01%
EBIT Next 5Y9.17%
FCF growth 1Y46.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.17%
OCF growth 3YN/A
OCF growth 5YN/A
GALAPAGOS NV / GLPG.AS FAQ
What is the fundamental rating for GLPG stock?
ChartMill assigns a fundamental rating of 3 / 10 to GLPG.AS.
What is the valuation status of GALAPAGOS NV (GLPG.AS) stock?
ChartMill assigns a valuation rating of 1 / 10 to GALAPAGOS NV (GLPG.AS). This can be considered as Overvalued.
What is the profitability of GLPG stock?
GALAPAGOS NV (GLPG.AS) has a profitability rating of 3 / 10.
What is the financial health of GALAPAGOS NV (GLPG.AS) stock?
The financial health rating of GALAPAGOS NV (GLPG.AS) is 5 / 10.